Key result
CHD polygenic risk score linked to ~69% higher major cardiovascular events risk per SD in T2D.
Why the study?
Current clinical risk prediction may misclassify individuals with type 2 diabetes as low cardiovascular risk and could be improved by adding a coronary heart disease polygenic risk score.
Does the addition of a CHD polygenic risk score to clinical risk assessment improve prediction of MACE in patients with type 2 diabetes without prior cardiovascular disease?
Cohort (n=10,556)
Does the addition of a CHD polygenic risk score to clinical risk assessment improve prediction of MACE in patients with type 2 diabetes without prior cardiovascular disease?
Answers are grounded in this paper and cite their sources.
The addition of a CHD polygenic risk score to standard clinical assessment significantly improves MACE prediction in patients with type 2 diabetes without prior cardiovascular disease, especially in those deemed low clinical risk.
OBJECTIVE: The recent availability of cardiovascular risk-reducing type 2 diabetes (T2D) therapies makes it imperative to optimally identify individuals who could derive benefit. Current clinical risk prediction may misclassify individuals as low risk and could be improved. Our aim was to determine the incremental prognostic value of a coronary heart disease (CHD) genome-wide polygenic risk score (PRS) to a clinical risk score in prediction of major adverse cardiovascular events (MACE) in patients with T2D. RESEARCH DESIGN AND METHODS: We evaluated 10,556 individuals with T2D aged 40-79 years without a prior cardiovascular hospitalization. We calculated 10-year clinical cardiovascular risk at the date of recruitment using the Pooled Cohort Equation (PCE Risk) and constructed a CHD PRS. The primary outcome was time to first MACE incidence, and we assessed the additional incremental predictive value of the CHD PRS to the PCE risk. RESULTS: At 10 years, there were 1,477 MACE. After adjustment for clinical risk, the CHD PRS was significantly associated with MACE (hazard ratio [HR] 1.69 per SD increase, 95% CI 1.60-1.79). Individuals with PCE Risk <7.5% but in the top quintile of CHD PRS had a significantly increased likelihood of MACE (HR 10.69, 95% CI 5.07-22.55) compared with those in the lowest. The addition of the PRS to the clinical risk score led to significant improvements in risk prediction, particularly in those at low clinical risk. CONCLUSIONS: The addition of a CHD PRS to clinical assessment improved MACE prediction in T2D individuals without prior cardiovascular disease, particularly in those at low clinical risk.
No takes yet. Share an insight, caveat, or question.
Mordi et al. (2024) conducted a cohort in Type 2 diabetes (n=10,556). Coronary heart disease polygenic risk score (PRS) vs. Clinical risk score (Pooled Cohort Equation) / lower PRS quintiles was evaluated on Time to first major adverse cardiovascular event (MACE) (HR 1.69, 95% CI 1.60-1.79). A coronary heart disease polygenic risk score was associated with incident major cardiovascular events in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: